Parkinson Disease

It’s difficult to diagnose Parkinson disease before some permanent neurological damage occurs. But tears may hold the key to earlier diagnoses.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

Investigators found that mindfulness yoga group can be an effective treatment option for patients with PD to manage both stress and symptoms.

The FDA has approved a scalpel-free method for the treatment of patients with Parkinson disease who experience tremors and are medication-resistant.

A large Asian population study supports the link between HCV and parkinsonism in that region, and associated treating HCV with reduced risk.

The inhaled INBRIJA therapy is indicated to treat 'off' episodes in patients taking carbidopa/levodopa.

There were no significant differences among tardive syndrome patients and healthy controls in either resting motor function or active motor function, and both group's symptoms improved with raised intensity.

The FDA’s post-marketing review concludes a five-month speculation which began when CNN reported the Acadia Pharmaceutical antipsychotic therapy was associated with more than 700 deaths of patients with Parkinson disease since June 2016.

A review of tardive dyskinesia epidemiology implicates newer "atypical" antipsychotics as well as older neuroleptics.

The symptoms of tardive dyskinesia and drug-induced parkinsonism can be remarkably similar, but an accurate diagnosis is critical when treatment for one condition may worsen the other.

If done ethically, the genetic database's collaboration with GSK could provide researchers what they really need to improve neurological care: the right patients in the right studies.

The FDA has granted an orphan drug designation to Asceneuron SA for ASN120290, for the treatment of progressive supranuclear palsy.

Researchers at Penn Medicine have found patients with more severe forms of neurodegenerative diseases possess more co-pathologies.

The executive vice president and chief medical officer of Biogen explained how crucial it is for potential DMTs to attacki the alpha-synuclein protein.

Trial patients' total maximal chorea score improved by 2 points in 8 weeks.

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

Blinded rating of remotely monitored patients supported the drug’s efficacy.

A deeper look a the sole FDA-approved treatment for Tardive Dyskinesia.